Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?

According to Zacks, Novavax (NVAX) is currently a #3 (Hold) on the Zacks Rank, but it has a VGM Score of B and a Momentum Style Score of B, with shares up 16.3% over the past four weeks. The consensus earnings estimate for fiscal year 2025 has increased by $0.98 to $2.03 per share due to three analysts revising their estimates upwards in the last 60 days, and NVAX boasts an average earnings surprise of 77.9%.

Analysis

Novavax (NVAX), a biotechnology company, currently holds a Zacks Rank #3 (Hold), yet exhibits several positive indicators according to Zacks' analysis. The stock has demonstrated strong recent performance, with shares appreciating 16.3% over the past four weeks, complemented by a Momentum Style Score of B and a VGM (Value, Growth, Momentum) Score of B. Significantly, analyst sentiment for fiscal 2025 appears to be improving; three analysts have revised their earnings estimates upward in the last 60 days, leading to a substantial increase in the Zacks Consensus Estimate by $0.98 to $2.03 per share. Furthermore, Novavax has a track record of significantly outperforming earnings expectations, evidenced by an average earnings surprise of 77.9%. While a #3 Rank typically suggests a neutral outlook, the presence of B-rated Style Scores in Momentum and VGM indicates potential upside, particularly as Zacks methodology suggests these scores are important for Hold-rated stocks and the article itself notes NVAX should be on investors' short list. The upward revisions in earnings estimates are a critical factor, as the Zacks Rank system prioritizes changes in earnings expectations.

Key Decisions for Investors

• Investors should consider Novavax for their watchlist, as its strong Momentum (B) and VGM (B) Style Scores, coupled with positive fiscal 2025 earnings estimate revisions, suggest potential despite its current Zacks #3 (Hold) rating.
• Closely monitor future analyst earnings estimate revisions for NVAX, as the recent upward adjustment in the FY2025 consensus to $2.03 per share and its significant 77.9% average earnings surprise are key positive catalysts highlighted by the report.
• Given the stock's 16.3% share price increase over the past four weeks and favorable Style Scores, investors with an appetite for momentum plays might find NVAX tactically interesting, while still acknowledging the broader neutral implication of its Hold rating.